Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingbao Heart Pill prospective cohort study in stable coronary heart disease
ChiCTR2300070975Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lingbao Huxin Dan in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: Efficacy of angina symptoms. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
Lingbao Huxin Dan
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on ChiCTR2300070975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070975.